BMC Psychiatry 25(1):170 Malagelada C et al (2025) European guideline on chronic nausea and vomitinga UEG and ESNM consensus for clinical management
Also hope you cover the National Priority Voucher pilot program in a future post
Eli Lillys oral small-molecule GLP-1, orforglipron (Foundayo), was FDA-approved April 1, 2026, but it is not tirzepatide and produces less weight loss (11.2% at 72 weeks)
One letter each was issued to a firm in South Africa, Canada, and Australia, and only one letter was issued to a domestic firm
There is no way to "fix" cloudiness, and injecting a cloudy solution introduces unknown risks
Craving Control : Naltrexone stands out for its ability to specifically target cravings by regulating dopamine, which can be a game-changer for those who struggle with emotional eating or intense food urges